NCT06101329 - Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102) | Biotech Hunter

Enrollment

253

Participants

Timeline

Start Date

November 17, 2023

Primary Completion Date

July 31, 2026

Study Completion Date

January 31, 2028

Conditions

Pre-Exposure Prophylaxis of HIV Infection

Interventions

DRUG

Lenacapavir Tablet

Tablets administered orally without regard of food

DRUG

Lenacapavir Injection

Injection administered subcutaneously

DRUG

Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)

200/300mg fixed dose combination (FDC) tablets administered orally

Trial Locations (11)

Cornell Clinical Trials Unit, New York Presbyterian Hospital - Weill Cornell Medicine, New York

Harlem Prevention Center CRS, New York

ICAP at Columbia University - Bronx Prevention Center, The Bronx

Penn Prevention Research Unit, Philadelphia

George Washington University Medical Faculty Associates, Washington D.C.

NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill, Chapel Hill

Ponce de Leon Center Clinical Research Site, Atlanta

UAB, 1917 Research Clinic, Birmingham

UCSD Antiviral Research Center (AVRC), San Diego

Fenway Health, Boston

Rutgers New Jesey Medical School - Clinical Research Center, Newark